{"pmid":32461330,"title":"Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis.","text":["Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis.","BACKGROUND: Coronavirus disease 2019 (COVID-19) has produced a significant health burden worldwide, especially in patients with cardiovascular comorbidities. The aim of this systematic review and meta-analysis was to assess the impact of underlying cardiovascular comorbidities and acute cardiac injury on in-hospital mortality risk. METHODS: PubMed, Embase and Web of Science were searched for publications that reported the relationship of underlying cardiovascular disease (CVD), hypertension and myocardial injury with in-hospital fatal outcomes in patients with COVID-19. The ORs were extracted and pooled. Subgroup and sensitivity analyses were performed to explore the potential sources of heterogeneity. RESULTS: A total of 10 studies were enrolled in this meta-analysis, including eight studies for CVD, seven for hypertension and eight for acute cardiac injury. The presence of CVD and hypertension was associated with higher odds of in-hospital mortality (unadjusted OR 4.85, 95% CI 3.07 to 7.70; I(2)=29%; unadjusted OR 3.67, 95% CI 2.31 to 5.83; I(2)=57%, respectively). Acute cardiac injury was also associated with a higher unadjusted odds of 21.15 (95% CI 10.19 to 43.94; I(2)=71%). CONCLUSION: COVID-19 patients with underlying cardiovascular comorbidities, including CVD and hypertension, may face a greater risk of fatal outcomes. Acute cardiac injury may act as a marker of mortality risk. Given the unadjusted results of our meta-analysis, future research are warranted.","Heart","Li, Xintao","Guan, Bo","Su, Tong","Liu, Wei","Chen, Mengyao","Bin Waleed, Khalid","Guan, Xumin","Gary, Tse","Zhu, Zhenyan","32461330"],"abstract":["BACKGROUND: Coronavirus disease 2019 (COVID-19) has produced a significant health burden worldwide, especially in patients with cardiovascular comorbidities. The aim of this systematic review and meta-analysis was to assess the impact of underlying cardiovascular comorbidities and acute cardiac injury on in-hospital mortality risk. METHODS: PubMed, Embase and Web of Science were searched for publications that reported the relationship of underlying cardiovascular disease (CVD), hypertension and myocardial injury with in-hospital fatal outcomes in patients with COVID-19. The ORs were extracted and pooled. Subgroup and sensitivity analyses were performed to explore the potential sources of heterogeneity. RESULTS: A total of 10 studies were enrolled in this meta-analysis, including eight studies for CVD, seven for hypertension and eight for acute cardiac injury. The presence of CVD and hypertension was associated with higher odds of in-hospital mortality (unadjusted OR 4.85, 95% CI 3.07 to 7.70; I(2)=29%; unadjusted OR 3.67, 95% CI 2.31 to 5.83; I(2)=57%, respectively). Acute cardiac injury was also associated with a higher unadjusted odds of 21.15 (95% CI 10.19 to 43.94; I(2)=71%). CONCLUSION: COVID-19 patients with underlying cardiovascular comorbidities, including CVD and hypertension, may face a greater risk of fatal outcomes. Acute cardiac injury may act as a marker of mortality risk. Given the unadjusted results of our meta-analysis, future research are warranted."],"journal":"Heart","authors":["Li, Xintao","Guan, Bo","Su, Tong","Liu, Wei","Chen, Mengyao","Bin Waleed, Khalid","Guan, Xumin","Gary, Tse","Zhu, Zhenyan"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32461330","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1136/heartjnl-2020-317062","keywords":["cardiac risk factors and prevention","epidemiology","global health","meta-analysis"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668079521490796544,"score":9.490897,"similar":[{"pmid":32173574,"pmcid":"PMC7194638","title":"Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis.","text":["Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis.","BACKGROUND: An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China; the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries. AIMS: The aim of this meta-analysis was to assess the prevalence of comorbidities in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients and the risk of underlying diseases in severe patients compared to non-severe patients. METHODS: A literature search was conducted using the databases PubMed, EMBASE, and Web of Science through February 25, 2020. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using random-effects models. RESULTS: Seven studies were included in the meta-analysis, including 1 576 infected patients. The results showed the most prevalent clinical symptom was fever (91.3%, 95% CI: 86-97%), followed by cough (67.7%, 95% CI: 59-76%), fatigue (51.0%, 95% CI: 34-68%) and dyspnea (30.4%, 95% CI: 21-40%). The most prevalent comorbidities were hypertension (21.1%, 95% CI: 13.0-27.2%) and diabetes (9.7%, 95% CI: 7.2-12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8-13.8%) and respiratory system disease (1.5%, 95% CI: 0.9-2.1%). When compared between severe and non-severe patients, the pooled OR of hypertension, respiratory system disease, and cardiovascular disease were 2.36 (95% CI: 1.46-3.83), 2.46 (95% CI: 1.76-3.44) and 3.42 (95% CI: 1.88-6.22) respectively. CONCLUSION: We assessed the prevalence of comorbidities in the COVID-19 patients and found that underlying disease, including hypertension, respiratory system disease and cardiovascular disease, may be risk factors for severe patients compared with non-severe patients.","Int J Infect Dis","Yang, Jing","Zheng, Ya","Gou, Xi","Pu, Ke","Chen, Zhaofeng","Guo, Qinghong","Ji, Rui","Wang, Haojia","Wang, Yuping","Zhou, Yongning","32173574"],"abstract":["BACKGROUND: An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China; the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries. AIMS: The aim of this meta-analysis was to assess the prevalence of comorbidities in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients and the risk of underlying diseases in severe patients compared to non-severe patients. METHODS: A literature search was conducted using the databases PubMed, EMBASE, and Web of Science through February 25, 2020. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using random-effects models. RESULTS: Seven studies were included in the meta-analysis, including 1 576 infected patients. The results showed the most prevalent clinical symptom was fever (91.3%, 95% CI: 86-97%), followed by cough (67.7%, 95% CI: 59-76%), fatigue (51.0%, 95% CI: 34-68%) and dyspnea (30.4%, 95% CI: 21-40%). The most prevalent comorbidities were hypertension (21.1%, 95% CI: 13.0-27.2%) and diabetes (9.7%, 95% CI: 7.2-12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8-13.8%) and respiratory system disease (1.5%, 95% CI: 0.9-2.1%). When compared between severe and non-severe patients, the pooled OR of hypertension, respiratory system disease, and cardiovascular disease were 2.36 (95% CI: 1.46-3.83), 2.46 (95% CI: 1.76-3.44) and 3.42 (95% CI: 1.88-6.22) respectively. CONCLUSION: We assessed the prevalence of comorbidities in the COVID-19 patients and found that underlying disease, including hypertension, respiratory system disease and cardiovascular disease, may be risk factors for severe patients compared with non-severe patients."],"journal":"Int J Infect Dis","authors":["Yang, Jing","Zheng, Ya","Gou, Xi","Pu, Ke","Chen, Zhaofeng","Guo, Qinghong","Ji, Rui","Wang, Haojia","Wang, Yuping","Zhou, Yongning"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32173574","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.ijid.2020.03.017","keywords":["covid-19","clinical characteristics","comorbidities","epidemiology","meta-analysis","sars-cov-2"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1666138492594290689,"score":371.98782},{"pmid":32402515,"title":"Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis.","text":["Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis.","Observational studies have reported an association between underlying cardiovascular diseases (CVD) and worse prognosis in COVID-19 patients, but this still remains unclear. We conducted a meta-analysis of recent studies that reported the association of CVD with worse prognosis and increased mortality in COVID-19 patients. Literature search through PubMed, the Cochrane Library, and Embase was completed by 2 reviewers from November 1, 2019 to April 20, 2020. Inclusion criteria were observational case-control or cohort studies on COVID-19 patients with a history of CVD included, which reported outcomes of COVID-19 infection severity, clearly outlined the definition of \"severe disease\" and with sample size >10. Data were abstracted independently by 2 authors. Studies were divided into 2 separate cohorts for analysis: severity (severe vs nonsevere) and mortality (nonsurvivors vs survivors). Data was pooled into a meta-analysis to estimate pooled odds ratio (OR) with 95% confidence interval (95% CI) for each outcome. A total of 18 studies (n=4858 patients) were included. Sixteen studies were from China, while 2 were from the United States. Pre-existing CVD was associated with a significantly increased risk of a severe form of COVID-19 (OR=3.14; 95% CI 2.32-4.24; I(2)=0%; Q=8.68, P= 0.73) and overall risk of COVID-19 all-cause mortality (OR=11.08; 95% CI: 2.59-47.32; I(2)=55%; P=0.11). However, this study did not find a significant association between previous history of CVD and mortality in severe COVID-19 disease (OR=1.72; 95% CI: 0.97-3.06, I(2)=0%, P=0.46). Pre-existing CVD is associated with worse outcomes among patients with COVID-19. Clinicians and policymakers need to take account of these findings in implementing risk stratification models.","Curr Probl Cardiol","Aggarwal, Gaurav","Cheruiyot, Isaac","Aggarwal, Saurabh","Wong, Johnny","Lippi, Giuseppe","Lavie, Carl J","Henry, Brandon M","Sanchis-Gomar, Fabian","32402515"],"abstract":["Observational studies have reported an association between underlying cardiovascular diseases (CVD) and worse prognosis in COVID-19 patients, but this still remains unclear. We conducted a meta-analysis of recent studies that reported the association of CVD with worse prognosis and increased mortality in COVID-19 patients. Literature search through PubMed, the Cochrane Library, and Embase was completed by 2 reviewers from November 1, 2019 to April 20, 2020. Inclusion criteria were observational case-control or cohort studies on COVID-19 patients with a history of CVD included, which reported outcomes of COVID-19 infection severity, clearly outlined the definition of \"severe disease\" and with sample size >10. Data were abstracted independently by 2 authors. Studies were divided into 2 separate cohorts for analysis: severity (severe vs nonsevere) and mortality (nonsurvivors vs survivors). Data was pooled into a meta-analysis to estimate pooled odds ratio (OR) with 95% confidence interval (95% CI) for each outcome. A total of 18 studies (n=4858 patients) were included. Sixteen studies were from China, while 2 were from the United States. Pre-existing CVD was associated with a significantly increased risk of a severe form of COVID-19 (OR=3.14; 95% CI 2.32-4.24; I(2)=0%; Q=8.68, P= 0.73) and overall risk of COVID-19 all-cause mortality (OR=11.08; 95% CI: 2.59-47.32; I(2)=55%; P=0.11). However, this study did not find a significant association between previous history of CVD and mortality in severe COVID-19 disease (OR=1.72; 95% CI: 0.97-3.06, I(2)=0%, P=0.46). Pre-existing CVD is associated with worse outcomes among patients with COVID-19. Clinicians and policymakers need to take account of these findings in implementing risk stratification models."],"journal":"Curr Probl Cardiol","authors":["Aggarwal, Gaurav","Cheruiyot, Isaac","Aggarwal, Saurabh","Wong, Johnny","Lippi, Giuseppe","Lavie, Carl J","Henry, Brandon M","Sanchis-Gomar, Fabian"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32402515","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.cpcardiol.2020.100617","locations":["China","United States"],"countries":["China","United States"],"countries_codes":["CHN|China","USA|United States"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666714494961713152,"score":355.57275},{"pmid":32489711,"pmcid":"PMC7220287","title":"Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis.","text":["Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis.","Coronavirus disease 2019 (COVID-19) has resulted in considerable morbidity and mortality worldwide since December 2019. In order to explore the effects of comorbid chronic diseases on clinical outcomes of COVID-19, a search was conducted in PubMed, Ovid MEDLINE, EMBASE, CDC, and NIH databases to April 25, 2020. A total of 24 peer-reviewed articles, including 10948 COVID-19 cases were selected. We found diabetes was present in 10.0%, coronary artery disease/cardiovascular disease (CAD/CVD) was in 8.0%, and hypertension was in 20.0%, which were much higher than that of chronic pulmonary disease (3.0%). Specifically, preexisting chronic conditions are strongly correlated with disease severity [Odds ratio (OR) 3.50, 95% CI 1.78 to 6.90], and being admitted to intensive care unit (ICU) (OR 3.36, 95% CI 1.67 to 6.76); in addition, compared to COVID-19 patients with no preexisting chronic diseases, COVID-19 patients who present with either diabetes, hypertension, CAD/CVD, or chronic pulmonary disease have a higher risk of developing severe disease, with an OR of 2.61 (95% CI 1.93 to 3.52), 2.84 (95% CI 2.22 to 3.63), 4.18 (95% CI 2.87 to 6.09) and 3.83 (95% CI 2.15 to 6.80), respectively. Surprisingly, we found no correlation between chronic conditions and increased risk of mortality (OR 2.09, 95% CI 0.26 to16.67). Taken together, cardio-metabolic diseases, such as diabetes, hypertension and CAD/CVD were more common than chronic pulmonary disease in COVID-19 patients, however, each comorbid disease was correlated with increased disease severity. After active treatment, increased risk of mortality in patients with preexisting chronic diseases may reduce.","Aging Dis","Liu, Hong","Chen, Shiyan","Liu, Min","Nie, Hao","Lu, Hongyun","32489711"],"abstract":["Coronavirus disease 2019 (COVID-19) has resulted in considerable morbidity and mortality worldwide since December 2019. In order to explore the effects of comorbid chronic diseases on clinical outcomes of COVID-19, a search was conducted in PubMed, Ovid MEDLINE, EMBASE, CDC, and NIH databases to April 25, 2020. A total of 24 peer-reviewed articles, including 10948 COVID-19 cases were selected. We found diabetes was present in 10.0%, coronary artery disease/cardiovascular disease (CAD/CVD) was in 8.0%, and hypertension was in 20.0%, which were much higher than that of chronic pulmonary disease (3.0%). Specifically, preexisting chronic conditions are strongly correlated with disease severity [Odds ratio (OR) 3.50, 95% CI 1.78 to 6.90], and being admitted to intensive care unit (ICU) (OR 3.36, 95% CI 1.67 to 6.76); in addition, compared to COVID-19 patients with no preexisting chronic diseases, COVID-19 patients who present with either diabetes, hypertension, CAD/CVD, or chronic pulmonary disease have a higher risk of developing severe disease, with an OR of 2.61 (95% CI 1.93 to 3.52), 2.84 (95% CI 2.22 to 3.63), 4.18 (95% CI 2.87 to 6.09) and 3.83 (95% CI 2.15 to 6.80), respectively. Surprisingly, we found no correlation between chronic conditions and increased risk of mortality (OR 2.09, 95% CI 0.26 to16.67). Taken together, cardio-metabolic diseases, such as diabetes, hypertension and CAD/CVD were more common than chronic pulmonary disease in COVID-19 patients, however, each comorbid disease was correlated with increased disease severity. After active treatment, increased risk of mortality in patients with preexisting chronic diseases may reduce."],"journal":"Aging Dis","authors":["Liu, Hong","Chen, Shiyan","Liu, Min","Nie, Hao","Lu, Hongyun"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32489711","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.14336/AD.2020.0502","keywords":["cardiovascular diseases","chronic pulmonary disease","coronavirus disease 2019 (covid-19)","diabetes","hypertension","meta-analysis"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668623433707028480,"score":349.61716},{"pmid":32232218,"pmcid":"PMC7096724","title":"Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis.","text":["Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis.","Introduction: In the beginning of 2020, an unexpected outbreak due to a new corona virus made the headlines all over the world. Exponential growth in the number of those affected makes this virus such a threat. The current meta-analysis aimed to estimate the prevalence of underlying disorders in hospitalized COVID-19 patients. Methods: A comprehensive systematic search was performed on PubMed, Scopus, Web of science, and Google scholar, to find articles published until 15 February 2020. All relevant articles that reported clinical characteristics and epidemiological information of hospitalized COVID-19 patients were included in the analysis. Results: The data of 76993 patients presented in 10 articles were included in this study. According to the meta-analysis, the pooled prevalence of hypertension, cardiovascular disease, smoking history and diabetes in people infected with SARS-CoV-2 were estimated as 16.37% (95%CI: 10.15%-23.65%), 12.11% (95%CI 4.40%-22.75%), 7.63% (95%CI 3.83%-12.43%) and 7.87% (95%CI 6.57%-9.28%), respectively. Conclusion: According to the findings of the present study, hypertension, cardiovascular diseases, diabetes mellitus, smoking, chronic obstructive pulmonary disease (COPD), malignancy, and chronic kidney disease were among the most prevalent underlying diseases among hospitalized COVID-19 patients, respectively.","Arch Acad Emerg Med","Emami, Amir","Javanmardi, Fatemeh","Pirbonyeh, Neda","Akbari, Ali","32232218"],"abstract":["Introduction: In the beginning of 2020, an unexpected outbreak due to a new corona virus made the headlines all over the world. Exponential growth in the number of those affected makes this virus such a threat. The current meta-analysis aimed to estimate the prevalence of underlying disorders in hospitalized COVID-19 patients. Methods: A comprehensive systematic search was performed on PubMed, Scopus, Web of science, and Google scholar, to find articles published until 15 February 2020. All relevant articles that reported clinical characteristics and epidemiological information of hospitalized COVID-19 patients were included in the analysis. Results: The data of 76993 patients presented in 10 articles were included in this study. According to the meta-analysis, the pooled prevalence of hypertension, cardiovascular disease, smoking history and diabetes in people infected with SARS-CoV-2 were estimated as 16.37% (95%CI: 10.15%-23.65%), 12.11% (95%CI 4.40%-22.75%), 7.63% (95%CI 3.83%-12.43%) and 7.87% (95%CI 6.57%-9.28%), respectively. Conclusion: According to the findings of the present study, hypertension, cardiovascular diseases, diabetes mellitus, smoking, chronic obstructive pulmonary disease (COPD), malignancy, and chronic kidney disease were among the most prevalent underlying diseases among hospitalized COVID-19 patients, respectively."],"journal":"Arch Acad Emerg Med","authors":["Emami, Amir","Javanmardi, Fatemeh","Pirbonyeh, Neda","Akbari, Ali"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32232218","source":"PubMed","week":"202014|Mar 30 - Apr 05","keywords":["covid-19","comorbidity","meta-analysis","severe acute respiratory syndrome coronavirus 2"],"topics":["Diagnosis"],"weight":1,"_version_":1666138492239872001,"score":330.96164},{"pmid":32484975,"title":"Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: an insight from a meta-analysis.","text":["Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: an insight from a meta-analysis.","Elevation of high-sensitivity cardiac troponin (hs-cTn) is a surrogate of myocardial injury, which appears to be a common complication of coronavirus disease 2019 (COVID-19). In this study, a meta-analysis was performed to clarify the association between myocardial injury assessed by hs-cTn levels and in-hospital mortality in patients with COVID-19. All existing studies on myocardial injury in patients with COVID-19 were retrieved from PubMed and EMBASE through April 13, 2020. In cases where overlap of the study population or enrollment period was found in articles published from the same hospitals, the article with the largest number of patients was only included in the analysis. The pooled odds ratio was calculated using inverse variance weighted random-effects models. Six observational studies which included a total of 1,231 patients met the search criteria. The percentage of patients with hs-cTn levels varied across the studies (13-41%). Elevated hs-cTn levels were significantly associated with an increase in in-hospital mortality (pooled odds ratio, 22.7; 95% confidence interval, 13.6-38.1; P<0.001) with a moderate heterogeneity (I(2) =28%), suggesting that elevated hs-cTn levels might be used as a reliable marker of disease severity early in the course of COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Aikawa, Tadao","Takagi, Hisato","Ishikawa, Kiyotake","Kuno, Toshiki","32484975"],"abstract":["Elevation of high-sensitivity cardiac troponin (hs-cTn) is a surrogate of myocardial injury, which appears to be a common complication of coronavirus disease 2019 (COVID-19). In this study, a meta-analysis was performed to clarify the association between myocardial injury assessed by hs-cTn levels and in-hospital mortality in patients with COVID-19. All existing studies on myocardial injury in patients with COVID-19 were retrieved from PubMed and EMBASE through April 13, 2020. In cases where overlap of the study population or enrollment period was found in articles published from the same hospitals, the article with the largest number of patients was only included in the analysis. The pooled odds ratio was calculated using inverse variance weighted random-effects models. Six observational studies which included a total of 1,231 patients met the search criteria. The percentage of patients with hs-cTn levels varied across the studies (13-41%). Elevated hs-cTn levels were significantly associated with an increase in in-hospital mortality (pooled odds ratio, 22.7; 95% confidence interval, 13.6-38.1; P<0.001) with a moderate heterogeneity (I(2) =28%), suggesting that elevated hs-cTn levels might be used as a reliable marker of disease severity early in the course of COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Aikawa, Tadao","Takagi, Hisato","Ishikawa, Kiyotake","Kuno, Toshiki"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32484975","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26108","keywords":["covid-19","coronavirus disease 2019","high-sensitivity cardiac troponin","in-hospital mortality","meta-analysis","myocardial injury"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668532114837995521,"score":324.6026}]}